These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15471821)

  • 1. 18F-FDG PET imaging in posttherapy monitoring of cervical cancers: from diagnosis to prognosis.
    Belhocine TZ
    J Nucl Med; 2004 Oct; 45(10):1602-4. PubMed ID: 15471821
    [No Abstract]   [Full Text] [Related]  

  • 2. Defining the priority of using 18F-FDG PET for recurrent cervical cancer.
    Yen TC; See LC; Chang TC; Huang KG; Ng KK; Tang SG; Chang YC; Hsueh S; Tsai CS; Hong JH; Lin CT; Chao A; Ma SY; Lin WJ; Fu YK; Fan CC; Lai CH
    J Nucl Med; 2004 Oct; 45(10):1632-9. PubMed ID: 15471826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.
    Schwarz JK; Siegel BA; Dehdashti F; Grigsby PW
    JAMA; 2007 Nov; 298(19):2289-95. PubMed ID: 18029833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
    Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
    Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. False-positive rate of posttherapy positron emission tomography in cervical cancer.
    Oxnard GR
    JAMA; 2008 Feb; 299(8):898; author reply 898. PubMed ID: 18314432
    [No Abstract]   [Full Text] [Related]  

  • 6. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome.
    Grigsby PW; Siegel BA; Dehdashti F; Rader J; Zoberi I
    J Clin Oncol; 2004 Jun; 22(11):2167-71. PubMed ID: 15169804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET Imaging in Cervical Cancer.
    Gandy N; Arshad MA; Park WE; Rockall AG; Barwick TD
    Semin Nucl Med; 2019 Nov; 49(6):461-470. PubMed ID: 31630730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of FDG-PET/CT imaging after radiation therapy.
    Grigsby PW
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S27-9. PubMed ID: 17727930
    [No Abstract]   [Full Text] [Related]  

  • 9. Peritoneal carcinomatosis from cervical cancer detected by F-18 FDG positron emission tomography.
    Spottswood SE; Lopatina OA; Fey GL; Boardman CH
    Clin Nucl Med; 2005 Jan; 30(1):56-9. PubMed ID: 15604978
    [No Abstract]   [Full Text] [Related]  

  • 10. PET/CT imaging to guide cervical cancer therapy.
    Grigsby PW
    Future Oncol; 2009 Sep; 5(7):953-8. PubMed ID: 19792965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET in cervical cancer--implications for 'staging,' treatment planning, assessment of prognosis, and prediction of response.
    Gold MA
    J Natl Compr Canc Netw; 2008 Jan; 6(1):37-45. PubMed ID: 18267057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET in the evaluation of cervical cancer.
    Macapinlac HA
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S171-2. PubMed ID: 16419203
    [No Abstract]   [Full Text] [Related]  

  • 13. 18F-FDG uptake in an ovary containing a hemorrhagic corpus luteal cyst: false-positive PET/CT in a patient with cervical carcinoma.
    Ames J; Blodgett T; Meltzer C
    AJR Am J Roentgenol; 2005 Oct; 185(4):1057-9. PubMed ID: 16177433
    [No Abstract]   [Full Text] [Related]  

  • 14. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area.
    Boughanim M; Leboulleux S; Rey A; Pham CT; Zafrani Y; Duvillard P; Lumbroso J; Haie-Meder C; Schlumberger M; Morice P
    J Clin Oncol; 2008 May; 26(15):2558-61. PubMed ID: 18487573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET for management of cervical and ovarian cancer.
    Havrilesky LJ; Kulasingam SL; Matchar DB; Myers ER
    Gynecol Oncol; 2005 Apr; 97(1):183-91. PubMed ID: 15790456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography imaging for gynecologic malignancy.
    Lai CH; Yen TC; Chang TC
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):37-41. PubMed ID: 17218850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-fluoro-2-deoxy-D-glucose-positron emission tomography (PET)/PET-computed tomography in carcinoma of the cervix.
    Kumar R; Dadparvar S
    Cancer; 2007 Oct; 110(8):1650-3. PubMed ID: 17763373
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
    Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
    J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular imaging in the management of cervical cancer.
    Lai CH; Yen TC; Ng KK
    J Formos Med Assoc; 2012 Aug; 111(8):412-20. PubMed ID: 22939658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4th International Cervical Cancer Conference: update on PET and cervical cancer.
    Grigsby PW
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S173-5. PubMed ID: 16419204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.